

Amendment Under 37 C.F.R. § 1.116
U.S. Serial No. 09/674,330

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Previously presented): An isolated polypeptide comprising the amino acid sequence shown in SEQ ID NO. 3, 8, or 9, or a homologue thereof having at least 95% sequence identity over the full length of the amino acid sequence, wherein said polypeptide suppresses smooth muscle cell proliferation.

2. (Previously presented): ~~The~~ An isolated polypeptide according to claim 1 comprising the amino acid sequence shown in SEQ ID NO. 3, 8 or 9.

3. (Currently amended): An isolated cDNA comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO. 3, 8, or 9, or a homologue thereof having at least 95% sequence identity over the full-length of the amino acid nucleotide sequence, wherein said polypeptide suppresses smooth muscle cell proliferation.

4. (Previously presented): ~~The~~ An isolated cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NO. 1, 6 or 10.

5. (Previously amended): ~~The~~ An isolated cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NO. 2 or 7.

Amendment Under 37 C.F.R. § 1.116
U.S. Serial No. 09/674,330

6. (Currently amended): A replication or expression vector comprising the cDNA according to any one of claims 3, 4, or 5, to 5.

7. (Original): A host cell transformed with the replication or expression vector according to claim 6.

8. (Previously presented): A method for producing a polypeptide of SEQ ID NO: 3, 8 or 9, or a homologue thereof having at least 95% sequence identity over the full length of the amino acid sequence, wherein said polypeptide suppresses smooth muscle cell proliferation, comprising culturing a host cell of claim 7 under a condition effective to express the polypeptide, and recovering the polypeptide so expressed.

9. (Canceled).

10. (Previously presented): A pharmaceutical composition comprising the polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent or carrier, or both.

11. (Canceled).

12. (Canceled).

Amendment Under 37 C.F.R. § 1.116
U.S. Serial No. 09/674,330

13. (Previously presented): A method for screening for an antagonist or agonist of a polypeptide according to claim 1 or 2, said method comprising preparing a first and second culture of a cell line, culturing said first cell line in the presence of one or more of said polypeptides, culturing said second cell line in the presence of one or more of said polypeptides and a test compound, and comparing the proliferation of the two cultures, thereby screening for an antagonist or agonist of a polypeptide according to claim 1 or 2.

14. (Previously presented): The An isolated cDNA according to claim 3, wherein the cDNA comprises a nucleotide sequence encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 3, 8 or 9, and wherein said polypeptide suppresses smooth muscle cell proliferation according to claim 2.

15. (New): An isolated cDNA comprising the nucleotide sequence shown in SEQ ID NO: 1, 6, 10, or a homologue thereof having at least 95% sequence identity over the full length of the nucleotide sequence, wherein said nucleotide sequence encodes a polypeptide that suppresses smooth muscle cell proliferation.